MeiraGTx Holdings plc

NasdaqGS MGTX

MeiraGTx Holdings plc Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 75.88 M

MeiraGTx Holdings plc Net Cash Used For Investing Activities is USD 75.88 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 395.97% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

MeiraGTx Holdings plc Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -25.64 M, a 58.54% change year over year.
MeiraGTx Holdings plc Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -61.84 M, a -32.75% change year over year.
MeiraGTx Holdings plc Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -46.58 M, a -45.91% change year over year.
MeiraGTx Holdings plc Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -31.93 M, a -143.39% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGS: MGTX

MeiraGTx Holdings plc

CEO	Dr. Alexandria Forbes Ph.D.
IPO Date	June 8, 2018
Location	United States
Headquarters	430 East 29th Street
Employees	387
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

Key trends

Past 5 years